These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32110202)

  • 1. Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma.
    Suzuki N; Tajiri K; Futsukaichi Y; Tanaka S; Murayama A; Entani T; Kobayashi S; Takahashi K; Fujii T; Imura J; Yasuda I
    Case Rep Gastroenterol; 2020; 14(1):63-69. PubMed ID: 32110202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
    Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
    Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.
    Terashima T; Yamashita T; Takata N; Toyama T; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
    Hepatol Res; 2020 Jul; 50(7):871-884. PubMed ID: 32307874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma.
    Adachi Y; Matsuki M; Watanabe H; Takase K; Kodama K; Matsui J; Funahashi Y; Nomoto K
    Cancer Invest; 2019; 37(4-5):185-198. PubMed ID: 31006280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
    Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study.
    Hidaka H; Uojima H; Nakazawa T; Shao X; Hara Y; Iwasaki S; Wada N; Kubota K; Tanaka Y; Shibuya A; Kanoh Y; Kokubu S; Koizumi W
    Hepatol Res; 2020 Sep; 50(9):1083-1090. PubMed ID: 32515895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib
    Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
    Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
    Honda S; Saito Y; Sawada K; Hasebe T; Nakajima S; Okumura T
    Intern Med; 2020 Mar; 59(5):657-662. PubMed ID: 31735795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma.
    Fan FM; Fleishman JS; Chen J; Chen ZS; Dong HH
    Drug Discov Today; 2024 Jun; 29(8):104069. PubMed ID: 38936692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis.
    Nakano M; Kuromatsu R; Niizeki T; Okamura S; Iwamoto H; Shimose S; Shirono T; Noda Y; Kamachi N; Koga H; Torimura T;
    Hepatol Commun; 2020 Aug; 4(8):1218-1228. PubMed ID: 32766480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case report.
    Miwa T; Kochi T; Watanabe K; Hanai T; Imai K; Suetsugu A; Takai K; Shiraki M; Katsumura N; Shimizu M
    J Rural Med; 2021 Apr; 16(2):102-110. PubMed ID: 33833836
    [No Abstract]   [Full Text] [Related]  

  • 13. Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma.
    Chuma M; Uojima H; Numata K; Hidaka H; Toyoda H; Hiraoka A; Tada T; Hirose S; Atsukawa M; Itokawa N; Arai T; Kako M; Nakazawa T; Wada N; Iwasaki S; Miura Y; Hishiki S; Nishigori S; Morimoto M; Hattori N; Ogushi K; Nozaki A; Fukuda H; Kagawa T; Michitaka K; Kumada T; Maeda S
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.
    Kotani K; Enomoto M; Okada M; Yoshida K; Motoyama H; Fujii H; Hagihara A; Uchida-Kobayashi S; Morikawa H; Murakami Y; Tamori A; Kawada N
    Clin J Gastroenterol; 2019 Aug; 12(4):355-360. PubMed ID: 31020569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].
    Watanabe T; Koyama N
    Nihon Yakurigaku Zasshi; 2019; 153(5):242-248. PubMed ID: 31092758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resection of "down-staged" advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report.
    Hou Z; Zhu K; Yang X; Zhou H; Chen P; Yu G; Zhu X; Cui Y; Song T; Li Q; Li H; Zhang T
    Transl Cancer Res; 2020 Aug; 9(8):4999-5007. PubMed ID: 35117862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines
    Ogasawara S; Mihara Y; Kondo R; Kusano H; Akiba J; Yano H
    Anticancer Res; 2019 Nov; 39(11):5973-5982. PubMed ID: 31704822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.
    Date E; Okamoto K; Fumita S; Kaneda H
    Invest New Drugs; 2018 Apr; 36(2):350-353. PubMed ID: 29018997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
    Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
    Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.
    Tamai T; Hayato S; Hojo S; Suzuki T; Okusaka T; Ikeda K; Kumada H
    J Clin Pharmacol; 2017 Sep; 57(9):1138-1147. PubMed ID: 28561918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.